Japanese University Will Research Marijuana's Medical Uses In First-Of-Its-Kind Collaboration With Australian Company
Portfolio Pulse from Nina Zdinjak
Cannatrek, an Australian plant-based medicine company, has signed an MoU with Mie University in Japan to research medical marijuana. This follows Japan's legalization of medical cannabis products. Jazz Pharmaceuticals (NASDAQ:JAZZ), which acquired GW Pharmaceuticals in 2021, has Epidiolex in its portfolio, a CBD medicine approved in the US and Europe for severe epilepsy. The MoU covers agronomic research, training, pharmaceutical supply chain, e-healthcare, regulation, and expert collaboration.
January 31, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals, which owns Epidiolex, a CBD medicine for epilepsy, could benefit from the medical marijuana research partnership between Cannatrek and Mie University in Japan.
The research partnership may lead to increased acceptance and potential new markets for CBD medicines like Epidiolex in Japan, which could positively impact Jazz Pharmaceuticals' market opportunities and stock price in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70